Despite the apparent neurotoxicity of amyloid-ß (Aß), recent clinical trials of Aß immunotherapy have not shown any clinical benefit in Alzheimer's disease (AD). Given this, clarification of the next generation therapeutic strategy in AD is warranted. Hypothetically, adiponectin might be involved in promoting amyloidogenic evolvability in reproduction, which may result in the adiponectin paradox through antagonistic pleiotropy mechanism in aging, leading to AD. Accordingly, preventing the adiponectin paradox by suppressing adiponectin signaling might prove therapeutic in AD.
CITATION STYLE
Waragai, M., Ho, G., Takamatsu, Y., Wada, R., Sugama, S., Takenouchi, T., … Hashimoto, M. (2020). Adiponectin Paradox as a Therapeutic Target in Alzheimer’s Disease. Journal of Alzheimer’s Disease, 76(4), 1249–1253. https://doi.org/10.3233/JAD-200416
Mendeley helps you to discover research relevant for your work.